Cilostazol and peripheral arterial disease

Bibliography

• Leng GC, Lees AJ, Fowkes FGR, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral vascular disease in the general population. Int J Epidemiol 1996;25:1172-81
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR. TASC II guidelines. Eur J Vasc Endovasc Surg 2007;33(Suppl.1):1-75
   PubMed Web of Science ®Google Scholar
• Schmieder F, Comerota A. Intermittent claudication; magnitude of the problem, patient evaluation and therapeutic strategies. Am J Cardiol 2001;87:D3-13
   Google Scholar
• Weitz JL, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-49
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Housely E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92
   PubMed Web of Science ®Google Scholar
• Caprie Steering Committee: a randomised, blinded, trial of Clopidrogel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Jones L, Griffin S, Palmer S, et al. Clinical effectiveness and cost-effectiveness of Clopidogrel and modified release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess 2004;8:1-196
   Web of Science ®Google Scholar
• Milani R, Lavie CJ. The role of exercise training in peripheral arterial disease. Vasc Med 2007;12:351-8
   PubMed Web of Science ®Google Scholar
• Bendermacher BL, Willigendael EM, Teijink JA, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006;(2):CD005263
   PubMedGoogle Scholar
• Creasy TS, McMillan PJ, Fletcher EW, et al. Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial. Eur J Vasc Surg 1990;4:135-40
   PubMedGoogle Scholar
• Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996;23:104-15
   PubMed Web of Science ®Google Scholar
• Desgischer S, Labs KH, Hochstrasser J, et al. Physical training for intermittent claudication: a comparison of structure rehabilitation versus home based training. Vasc Med 2002;7:109-15
   PubMed Web of Science ®Google Scholar
• Nielsen SL, Larsen B, Prahl M, et al. Hospital training compared with home training in patients with intermittent claudication. Ugeskr Laeger 1977;139:2733-6
   PubMedGoogle Scholar
• Bendermacher BL, Kruidenier LM, Nicolaï SP, et al. Supervised xercise therapy for intermittent claudication. Acta Chir Belg 2007;107:616-22
   PubMed Web of Science ®Google Scholar
• Ratcliff DA, Puttick M, Libertiny G, et al. Supervised exercise training for intermittent claudication lasting benefit at three years. Eur J Vasc Surg 2007;34:322-6
   Google Scholar
• Belli AM, Jackson J, Ellis DJ. Interventional radiological procedures. In: Clement DL, Shepard JT, editors. Vascular diseases in the limbs: mechanisms and principles of treatment. St Louis: Mosley Year Book; 1993. p. 239-58
   Google Scholar
• Schillinger M, Sabeti S. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88
   PubMed Web of Science ®Google Scholar
• Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomised control trial. J Vasc Surg 1997;26:551-7
   PubMed Web of Science ®Google Scholar
• De Vries SO, Visser K, De Vries JA, et al. Intermittent claudication cost effectiveness of revascularisation versus exercise therapy. Radiology 2002;222:25-36
   PubMed Web of Science ®Google Scholar
• Hunink MG, Wong JB, Donaldson MC, et al. Revascularisation for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995;274:165-71
   PubMed Web of Science ®Google Scholar
• Visser K, De Vries SO, Kitslaar PJ, et al. Cost effectiveness of diagnostic imaging work up and treatment for patients with intermittent claudication in The Netherlands. Eur J Vasc Surg 2003;25:213-23
   Google Scholar
• Visser K, Kuntz KM, Donaldson MC, et al. Pretreatment imaging workup for patients with intermittent claudication: a cost effective analysis. J Vasc Interv Radiol 2003;12:53-62
   Google Scholar
• Taniguchi K, Ohtani H, Okemoto T, et al. Possible case of potentiation of the antiplatelet effect of cilostazol by grapefruit juice. J Clin Pharm Ther 2007;32:457-9
   PubMed Web of Science ®Google Scholar
• Fujinaga K, Onoda K, Yamamoto K, et al. Locally applied cilostazol suppresses neo-intimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg 2004;128:357-63
   PubMed Web of Science ®Google Scholar
• Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double blind, placebo-controlled study. Vasc Endovasc Surg 2002;36:83-91
   PubMedGoogle Scholar
• Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001;87:28D-33D
   Google Scholar
• Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE Study (Cilostazol: a Study in Long Term Effects). J Vasc Surg 2008;47:330-6
   PubMed Web of Science ®Google Scholar
• Falconer TM, Eikelboom JW, Hankey GJ, et al. Management of peripheral arterial disease in the elderly: focus on cilostazol. Clin Inter Aging 2008;3:17-23
   PubMed Web of Science ®Google Scholar
• Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35:1144-9
   PubMed Web of Science ®Google Scholar
• Hiroko K, Kazuo N, Terutoshi S, et al. The effect of cilostazol on P-selectin and cyclic AMP in the thrombocyte. Jap J Clin Pharmacol Ther 2000;31:45-6
   Google Scholar
• Stone WM, Demaerschalk BM, Fowl RJ, et al. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. J Stroke Cerebrovas Dis 2008;17:129-33
   PubMedGoogle Scholar
• Huang Y, Cheung Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic strike: a randomised, double-blind, pilot study. Lancet Neurol 2008;7:494-9
   PubMed Web of Science ®Google Scholar
• Zhao H, Quilley J, Montrose DC, et al. Differential effects of phosphodiesterase PDE-3/PDE-4 specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty. Am J Physiol Heart Circ Physiol 2007;292:2973-81
   PubMed Web of Science ®Google Scholar
• Wu SN, Liu SI, Huang MH. Cilostazol, an inhibitor of type 3 phosphodiesterase, stimulates large-conductance, calcium-activated potassium channels in pituitary GH3 cells and pheochromocytoma PC12 cells. Endocrinology 2004;145:1175-84
   PubMed Web of Science ®Google Scholar
• Sidaway AN. Myointimal hyperplasia: basic science and clinical consideration. Semin Vasc Surg 1998;11(3):142-8
   PubMedGoogle Scholar
• Takahashi S, Oida K, Fujiwara R. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. Cardiovasc Pharmacol 1992;20:900-6
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Onoda K, Sawada Y. Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg 2007;13:322-30
   PubMedGoogle Scholar
• Reilly MP, Mohler IE. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48-56
   PubMed Web of Science ®Google Scholar
• Iida O, Nanto S, Uematsu M, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008;48:144-9
   PubMed Web of Science ®Google Scholar
• Lee SW, Park SW, Kim YH, et al. Drug eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy after Drug-eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-7
   PubMed Web of Science ®Google Scholar
• Biondi Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomised clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008;155:1081-9
   PubMed Web of Science ®Google Scholar
• Takazakura E, Osawa K, Hamamatsu K. Effect of cilostazol (Pletal) on serum lipid levels in diabetic patients. Jpn Pharmacol Ther 1989;17:311-5
   Google Scholar
• Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 1998;18:1942-7
   PubMed Web of Science ®Google Scholar
• Nakamura N, Hamazaki T, Johkaji H, et al. Effects of cilostazol on lipid and fatty acid metabolism. Clin Exp Med 2003;2:180-4
   PubMed Web of Science ®Google Scholar
• Nakamura N, Osawa H, Yamabe H, et al. Effects of cilostazol on lipid and fatty acid metabolism. Clin Exp Med 2005;4:170-3
   PubMed Web of Science ®Google Scholar
• Okuda Y, Kimua Y, Yamashita K. Cilostazol. Cardiovasc Drug Rev 1993;11:451
   Google Scholar
• Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008;(1):CD003748
   Google Scholar
• Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine 1999;159(17):2041-50
   PubMed Web of Science ®Google Scholar
• Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication : results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98(7):678-86
   PubMed Web of Science ®Google Scholar
• Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine 2000;109(7):523-30
   PubMed Web of Science ®Google Scholar
• Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al.Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27(2):267-74
   PubMed Web of Science ®Google Scholar
• Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al.Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovas Surg 2002;36(2):83-91
   PubMedGoogle Scholar
• Serracino Inglott F, Owen G, Carter A, et al. All patients benefit equally from a supervised exercise program for claudication. Vasc Endovasc Surg 2007;41:212-6
   PubMedGoogle Scholar
• Available from: http://www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/NHSFinancialReforms/DH_081226 [Last accessed June 2008]
   Google Scholar